NREP
NEW REPRESENTATIVE AT IB RECEIVED
18/10/2024
Voltar para busca
Dado oficial do USPTO
CEVEC
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CEVEC
ST13
US500000079035160Classe
1, 5, 42, 44
Pedido
79035160
Registro
3405717
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
60
Atualização mais recente
18/10/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 44
Data de depósito
03/11/2006
Data de registro
01/04/2008
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/12/2017
Última transação
09/08/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
51105 Köln, DE
Examinador
KUNG, KAELIE
Unidade examinadora
L30
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH
Representantes
Dyan M. House Baker & Mckenzie, LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical preparations for scientific purposes and biological products for scientific purposes in the nature of microorganismseukaryotic cell culture linespolypeptidesproteinsnucleic acidsviral vectors and gene expression vectorsexcept for medical and veterinary purposes; chemical and biological preparations other than for medical or veterinary purposesfor use in research and characterization of diseasesdiagnostic preparations for scientific and research use; cultures of microorganisms for scientific purposeseukaryotic cell culture lines for scientific purposes
Classe 5
Medicaments for the treatment of cancertumorous diseasesproliferative diseasesallergiesauto-immune diseasesinflammationinflammatory diseasesinfectious diseasesosteoporosisgraft versus host and host versus graft diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesrestenosismetabolic disordersneurological disordersdiabetesB cell malignancyrheumatoid arthritisimmunological disordersparasitic reactionsskin diseasesneurodegenerative diseases and cardio-vascular diseases; pharmaceutical and veterinary preparations for use in the treatment of cancertumorous diseasesproliferative diseasesallergiesauto-immune diseasesinflammationinflammatory diseasesinfectious diseasesosteoporosisgraft versus host and host versus graft diseasestransplant rejectioncoronary heart diseasesminimal residual diseasesrestenosismetabolic disordersneurological disordersdiabetesB cell malignancyrheumatoid arthritisimmunological disordersparasitic reactionsskin diseasesneurodegenerative diseases and cardio-vascular diseases; chemical and biological preparations for medical usefor medical diagnosis and analysis; eukaryotic cell culture linesmicroorganismspolypeptidesnucleic acids for medical and medical diagnostic purposes
Classe 42
Scientific and industrial research and consulting servicesin particular in the fields of molecular biologybiotechnologygenetics; pharmaceutical research and development; medical research and development of methods of medical therapy; scientific and technological services in the nature of breedingrecoveryoptimizationsynthesis and modification of eukaryotic cell culture linesmicro-organismspolypeptidesnucleic acids for third parties; research services in the fields of medicine and pharmaceuticals; medical and scientific researchconducting clinical trials for third parties
Classe 44
Medical and veterinary services; medical servicesbreedingrecoveryoptimizationsynthesis and modification of eukaryotic cell culture linesmicro-organismspolypeptidesnucleic acids for third parties; consulting services in the fields of medicine and pharmaceuticals
Publicações
Histórico de despachos e eventos da marca no USPTO.
60 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/08/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
09/08/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/08/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/08/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/08/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/08/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
19/11/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/08/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
21/08/2023
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
21/08/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/08/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/08/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
21/08/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
21/08/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
13/07/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
13/07/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/07/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/07/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/06/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
11/06/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/06/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/06/2021
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
19/10/2018
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
11/09/2018
INPC
INVALIDATION PROCESSED
11/09/2018
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
23/08/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/08/2018
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
23/12/2017
71AG
REGISTERED-SEC.71 ACCEPTED
23/12/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/12/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/11/2017
ES71
TEAS SECTION 71 RECEIVED
15/11/2017
RNWL
INTERNATIONAL REGISTRATION RENEWED
17/11/2016
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - MAILED
11/04/2014
C75A
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
11/04/2014
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/04/2014
715F
REGISTERED - SEC. 71 & SEC. 15 FILED
10/03/2014
ES75
TEAS SECTION 71 & 15 RECEIVED
10/03/2014
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
22/12/2012
FICS
FINAL DISPOSITION NOTICE SENT TO IB
17/07/2008
FIMP
FINAL DISPOSITION PROCESSED
17/07/2008
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/07/2008
R.PR
REGISTERED-PRINCIPAL REGISTER
01/04/2008
PUBO
PUBLISHED FOR OPPOSITION
15/01/2008
NPUB
NOTICE OF PUBLICATION
26/12/2007
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
11/12/2007
ALIE
ASSIGNED TO LIE
10/12/2007
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/11/2007
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/10/2007
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/10/2007
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/10/2007
RFNT
REFUSAL PROCESSED BY IB
03/05/2007
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/04/2007
RFRR
REFUSAL PROCESSED BY MPU
12/04/2007
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/04/2007
CNRT
NON-FINAL ACTION WRITTEN
10/04/2007
DOCK
ASSIGNED TO EXAMINER
30/03/2007
NWAP
NEW APPLICATION ENTERED
30/03/2007
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
29/03/2007
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CEVEC ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.